A Deep Dive Into Cardiff Oncology’s Clinical Progress 

Photo of author
Written By Kris Enyinnaya

Cardiff Oncology, Inc. (NASDAQ: CRDF) recently reported its fourth-quarter and full-year 2023 financial results and corporate update. 

The earnings call, held on February 29, 2024, revealed significant developments in the company’s clinical trials and strategic decisions. This analysis delves into the key highlights of the earnings call and Cardiff Oncology’s forward-looking statements.

Forward-Looking Statements and Risk Factors

The conference call commenced with a cautionary note on forward-looking statements, emphasizing the inherent risks and uncertainties involved.

Credit: DepositPhotos

Cardiff Oncology’s management acknowledged the potential discrepancies between anticipated outcomes and actual results, urging investors to consider the risk factors outlined in the company’s annual report filed with the SEC.

Read More: Significant Decrease in Short Interest for Kingsoft Cloud Holdings Limited (NASDAQ: KC)

CEO’s Opening Remarks

Chief Executive Officer Mark Erlander provided an overview of Cardiff Oncology’s pivotal decisions and clinical progress in 2023. 

Notably, the company transitioned its metastatic colorectal cancer (mCRC) program from the second-line to the first-line setting based on compelling clinical signals and FDA support. 

Erlander highlighted the significance of new data from the ONSEMBLE trial, reinforcing the company’s strategic shift and validating its first-line program.

Significant Announcements in 2023

Erlander outlined the transformative events of 2023, including the discovery of a novel mechanism of action for onvansertib, Cardiff Oncology’s flagship drug candidate. 

The company received FDA support for its first-line mCRC clinical development plan and announced strategic collaborations, including the Pfizer Ignite program, aimed at enhancing clinical execution.

Also Read: Chemours Faces Executive Misconduct and Financial Implications

Clinical Data and Trials

Jamie Levine, Chief Financial Officer, took over the presentation due to Erlander’s voice issues. Levine discussed Cardiff Oncology’s clinical data and trials, particularly focusing on the ONSEMBLE trial’s findings. 

The company identified a subgroup of patients with promising responses, prompting the decision to discontinue the trial and prioritize the first-line setting. Levine highlighted the initiation of the CRDF-004 trial and emphasized Pfizer Ignite’s role in clinical execution.

Review of Clinical Data

Dr. Fairooz Kabbinavar, Chief Medical Officer, provided insights into Cardiff Oncology’s clinical data. With extensive oncology experience, Dr. Kabbinavar presented key findings from the ONSEMBLE trial, emphasizing the validation of the company’s first-line strategy. 

Potential Challenges Acknowledged 

The conference call commenced with a cautionary note on forward-looking statements, emphasizing the inherent risks and uncertainties involved. 

Cardiff Oncology’s management acknowledged the potential discrepancies between anticipated outcomes and actual results, urging investors to consider the risk factors outlined in the company’s annual report filed with the SEC.

Commitment to Transparency 

The management’s emphasis on the uncertainties inherent in forward-looking statements reflects Cardiff Oncology’s commitment to transparency and responsible communication with investors. 

By highlighting the risk factors outlined in the annual report, the management aims to ensure that investors have a comprehensive understanding of the potential challenges and uncertainties that could impact the company’s future performance.

Credit: DepositPhotos


Read Next: Lytus Technologies Redefines Cloud Computing with Lytus Cloud


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.